A Second Opinion: Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity

Executed on:Jun 14, 2024 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Mayo ClinicProfessor of Medicine & Consultant, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine at the Mayo Clinic.
Manages 40 patients monthly with obesity.
His lab studies the effects of obesity and how body fat (adipose tissue) and body fat distribution influence health; research involves measuring free fatty acid release in order to relate these factors to organ and tissue function with a goal of understanding the regulation of body fat and body fat distribution, in hopes of developing novel approaches to improve the health of humans affected by obesity or excess fat.

Interview Goal

This conversation will examine the updated results of Structure Therapeutics's GSBR-1290 Phase 2a clinical trial data on GSBR-1290 evaluating the safety and efficacy in individuals with obesity

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.